Mylan N.V. (NASDAQ:MYL):
Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association’s 77th Scientific Sessions.
The company is trading up by 0.96% since yesterday’s close of $39.71.
Mylan N.V., launched on July 7, 2014, is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The Business’s Cold-EEZE family of brands includes OTC cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the United States. The North America segment is primarily made up of its operations in the United States and Canada. The Europe segment is made up its operations in approximately 35 countries within the region. The Rest of World segment is primarily made up of its operations in India, Australia, Japan and New Zealand. Also included in the Rest of World segment are its operations in markets, which include countries in Africa (including South Africa), as well as Brazil and other countries throughout Asia and the Middle East. The Company conducts active pharmaceutical ingredient (API) business through Mylan Laboratories Limited (Mylan India). As of December 31, 2016, it offers product portfolios, including approximately 7,500 marketed products around the world, to customers in over 165 countries and territories. It operates a global vertically integrated manufacturing platform around the world and API operations. It also operates research and development (R&D) network that delivers product pipeline, including a range of dosage forms, therapeutic categories and biosimilars..
Company chares are trading at $40.09 which is just over the 50 day moving average which is $38.49 and just above the 200 day moving average of $38.98. The 50 day moving average was up $1.60 and the 200 day average went up by +2.86%.
The company’s P/E ratio is 40.05 and market cap is 21.49B. In the latest earnings report the EPS was $1.00 and is expected to be $5.18 for the current year with 535,950,000 shares presently outstanding. Next quarter’s EPS is estimated at $1.46 with next year’s EPS anticipated to be $5.66.
Short traders are more bullish lately if you take into consideration the decrease in short interest. The stock saw a fall in short interest of -5.52% as of April 28, 2017 from the last reporting period. Short shares fell from 17,975,806 to 16,983,681 over that period. Days to cover decreased from 4.2 to 2.8 and the percentage of shorted shares is 0.03% as of April 28.
Wall Street analysts have released ratings on Mylan N.V. of late. On May 22 the company was rated “Overweight” according to a Barclays report a boost from the previous “Equal-weight” rating. Mizuho started covering the stock giving it an initial rating of “Buy”.
On October 10, 2016 the stock rating was set at “Strong Buy” by Raymond James which was a boost from the previous “Market Perform” rating. On October 10 the company was changed to a “Strong Buy” according to a report which is up from the previous “” rating.
On September 30 Leerink Swann kept the company rating at “” and lowered the price expectation from $55.00 to $45.00. On September 23 Deutsche Bank held the company rating at “Buy” and moved down the price target to $58.00 from $65.00.